KRAS and cancer: To determine whether cancer cells overexpressing CDC25 are sensitive to treatment with the compounds identified in this study, we initially selected cell lines that carry activating bi-allelic mutation of K-Ras (G12S) and are reported to express high level of CDC25B (http://www.proteinatlas.org/).